Allergic conjunctivitis as a risk factor for regression and haze after photorefractive keratectomy.
OBJECTIVE
To analyze the relation between allergic conjunctivitis and the results of photorefractive keratectomy performed with an excimer laser in myopic eyes.


METHODS
Fifty-seven myopic eyes in 57 Japanese patients were classified into three groups: a normal group (30 eyes of 30 patients), a treatment group composed of eyes with allergic conjunctivitis that were treated with fluorometholone and cromolyn sodium eyedrops from month 3 until the end of the 12- to 18-month follow-up period (16 eyes of 16 patients), and a no-treatment group composed of eyes with allergic conjunctivitis that received no allergic treatment until the end of the follow-up period (11 eyes of 11 patients). Preoperative and postoperative examinations included evaluation of corrected and uncorrected visual acuity and grading of corneal haze.


RESULTS
In the no-treatment group, the mean corneal haze score +/- SD of 0.8 +/- 0.98 was significantly greater than the normal group score of 0.38 +/- 0.49 (P = .02). There was no significant difference in the haze score between the treated and normal groups. A refractive outcome of +/- 1 diopter was obtained in 30 (100%) of the 30 patients in the normal group, 15 (93.8%) of 16 patients in the treatment group, and four (36.4%) of the 11 patients in the no-treatment group. Visual acuity was 20/40 or better after photorefractive keratectomy in 30 patients (100%) in the normal group, 15 patients (93.8%) in the treatment group, and six patients (54.5%) in the no-treatment group.


CONCLUSIONS
These findings suggest that untreated allergic conjunctivitis is a significant risk factor for haze and myopic regression after photorefractive keratectomy.
Yang
H Y
HY
Department of Ophthalmology, Tokyo Dental College, Chiba, Japan. VYB04652@niftyserve.or.jp
Fujishima
H
H
Toda
I
I
Itoh
S
S
Bissen-Miyajima
H
H
Shimazaki
J
J
Tsubota
K
K
D000328:Adult; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D003233:Conjunctivitis, Allergic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D003315:Cornea / Q000601:surgery*; D003318:Corneal Opacity / Q000209:etiology* / Q000503:physiopathology; D004205:Cromolyn Sodium / Q000627:therapeutic use; D005260:Female; D005469:Fluorometholone / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000209:etiology / Q000503:physiopathology / Q000601:surgery*; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D012029:Refraction, Ocular; D012307:Risk Factors; D014792:Visual Acuity
D018926:Anti-Allergic Agents; D004205:Cromolyn Sodium; D005469:Fluorometholone